Skip to content
Screener

Pacira BioSciences, Inc. PCRX Total Liabilities

Total Liabilities at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$38.53M-97.2%
AtriCure logo
AtriCureATRC
$160.21M+11.0%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$973.83M-14.0%
Enterprise value$1.24B+4.9%
P/E189.5×—
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%—
Net margin0.7%—
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%—
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028871
Line itemMarch 31,2026December 31,2025
Contingent consideration15,78918,066
Deferred tax liabilities4,0934,213
Other liabilities24,61120,572
Total liabilities554,641571,806
Commitments and contingencies (Note 16)
Stockholders’ equity:
Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at March 31, 2026 and December 31, 2025——
Common stock, par value $0.001; 250,000,000 shares authorized; 48,328,201 shares issued and 39,309,610 shares outstanding at March 31, 2026 and 47,890,777 shares issued and 41,116,739 shares outstanding at December 31, 20254848

Item 1. FINANCIAL STATEMENTS (Unaudited)

FAQ

What is Pacira BioSciences, Inc.'s total liabilities?
Pacira BioSciences, Inc. (PCRX) reported total liabilities of $554.64M in Q1 2026.
How has Pacira BioSciences, Inc.'s total liabilities changed year-over-year?
Pacira BioSciences, Inc.'s total liabilities decreased by 29.6% year-over-year, from $788.13M to $554.64M.
What is the long-term trend for Pacira BioSciences, Inc.'s total liabilities?
Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s total liabilities has grown at a -2.7% compound annual growth rate (CAGR), from $654.83M to $571.81M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Pacira BioSciences, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude